OCT-4, an embryonic stem cell marker expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma

Iranian Journal of Cancer Prevention

Volumn 2, Issue 4, 2009, Pages 167-173

  Madjd, Z ^a,b   Hashemi, F ^a   Shayanfar, N ^a   Farahani, E ^a   Zarnani, A H ^a,c   Sharifi, A M ^a   Akbari, M E ^b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Breast cancer; Cancer stem cells; Oct 4; Seminoma

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4;

ADULT; AGED; ARTICLE; BRAIN CANCER; BREAST CARCINOMA; CARCINOGENESIS; CELL NUCLEUS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; EMBRYONIC STEM CELL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MENINGIOMA; OLIGODENDROGLIOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEMINOMA; TESTIS CARCINOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE DISTRIBUTION;

EID: 77953387142     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004 Sep 20; 23(43):7274-82.
2. Chang CC. Recent translational research: stem cells as the roots of breast cancer. Breast Cancer Res. 2006; 8(1):103.
3. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003 Dec; 3(12):895-902.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 Nov; 414(6859):105-11.
5. Romano G. The role of adult stem cells in carcinogenesis. Drug News Perspect. 2005 Nov; 18(9): 555-9.
6. Matin MM, Walsh JR, Gokhale PJ, Draper JS, Bahrami AR, Morton I, et al. Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. Stem Cells. 2004; 22(5):659-68.
7. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000 Apr; 24(4):372-6.
8. Clark AT, Rodriguez RT, Bodnar MS, Abeyta MJ, Cedars MI, Turek PJ, et al. Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells. 2004; 22(2):169-79.
9. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 2007 Apr 1; 120(7):1598-602.
10. Sotomayor P, Godoy A, Smith GJ, Huss WJ. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate. 2009 Mar 1; 69(4):401-10.
11. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell. 2003 Nov; 4(5):361-70.
12. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005 May 6; 121(3):465-77.
13. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun. 2009 May 29; 383(2):157-62.
14. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2004 Nov 1; 101(9):2006-10.
15. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 2004 Jul; 51(1):1-28.
16. Cohnheim J. Ueber entzundung und eiterung. Path Anat Physiol Klin Med. 1867; 40:1-79.
17. Durante F. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memori ed Osservazioni di Chirugia Practica 1874; 11:217-26.
18. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun. 2009; 9:4.
19. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol. 2003 Aug; 200(5):633-9.
20. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004 Jun; 203(2):661-71.
21. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2004 Aug 27.
22. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol. 2004 Jul; 28(7):935-40.
23. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun. 2007; 7:17.
24. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005 Nov 1; 117(2):248-55.
25. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004 Oct; 28(10):1341-6.
26. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer. 2005 Nov 15; 104(10):2255-65.
27. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, Jones SB, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13350-5.
28. Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004 Jul 15; 64(14):4736-43.
29. Ruangpratheep C, Lohachittranond C, Poonpracha T, Punyarit P. OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview. J Med Assoc Thai. 2005 Nov; 88 Suppl 3:S281-9.